The role of the novel oral anticoagulants (NOACs). What the GP needs to know. – QI&CPD – Category 1

After completing this module, GPs will be better able to:

1. Describe the role anticoagulation plays in stroke prevention in non-valvular atrial fibrillation (NVAF) and at least one additional risk factor for stroke, and in the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE))
2. Discuss the indications for anticoagulation therapy in patients with NVAF and at least one additional risk factor for stroke, and in VTE
3. Evaluate safety factors associated with initiation of anticoagulants, such as stroke risk in patients with NVAF and at least one additional risk factor for stroke and the risk of bleeding
4. Review the evidence regarding novel oral anticoagulant treatment options for patients with NVAF and at least one additional risk factor for stroke and patients with VTE
5. Determine how to most effectively initiate and manage the novel oral anticoagulants (NOACs) for the:
   • prevention of stroke in patients with NVAF and at least one additional risk factor for stroke
   • management of DVT, (and PE if applicable), in general practice